Radiology:小心漏诊乳腺癌患者腋窝前哨淋巴结!

2020-04-02 shaosai MedSci原创

越来越多的乳腺癌患者在新辅助化疗(NAC)后进行了前哨淋巴结活检(SLNB)。

背景

越来越多的乳腺癌患者在新辅助化疗(NAC)后进行了前哨淋巴结活检(SLNB)。

目的

本研究旨在评价与乳腺癌患者NAC后前哨淋巴结漏诊相关的术前乳腺MRI、临床病例特征。


材料与方法

本研究纳入了行NAC后SLNB的乳腺癌患者。由两名放射科医师独立评估治疗器乳腺MRI腋淋巴结特征(数量、淋巴结周围浸润征象、淋巴结皮质厚度和最大径)。利用卡方检验和或卡方趋势测试及多元Logistic回归分析评价腋淋巴结临床-病理、影像学特征与前哨淋巴结识别的相关性。

结果

共有276名妇女(平均年龄±标准差,48岁±9岁;范围27-68岁)被纳入研究。在276名患者中,有252名患者(91%)发现了前哨淋巴结。多变量回归分析显示临床T期越高(3期或4期)(2名放射科医生分别为:OR = 5.2,P = .004;OR = 4.6,P = .01),使用影像检查方法(2名放射科医生分别为:OR = 4.3,P = .04 OR = 3.9,P = .046),可疑腋窝淋巴结越多(10个或更多)(2名放射科医生分别为:OR = 11. 5,P = .002;OR = 8.3,P = .01),以及存在结节周围浸润(2名放射科医生分别为:OR = 7.0,P = .002;OR = 7.5,P = .003)与检出前哨淋巴结失败有关。

结论

在乳腺癌患者新辅助化疗前乳腺MRI检查中,可疑腋窝淋巴结越多和治疗前MRI检查时出现腋窝淋巴结周围浸润、较高的临床T分期以及使用影像学检查方法与乳腺癌患者新辅助化疗后前哨淋巴结漏诊具有独立相关性。

原始出处:

Kim WH, Kim HJ, Park CS.et al. Axillary Nodal Burden Assessed with Pretreatment Breast MRI Is Associated with Failed Sentinel Lymph Node Identification after Neoadjuvant Chemotherapy for Breast Cancer. DOI: 10.1148/radiol.2020191639

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1293092, encodeId=6edb12930922f, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Sat Apr 04 03:03:08 CST 2020, time=2020-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407389, encodeId=4114140e38966, content=<a href='/topic/show?id=144966640f8' target=_blank style='color:#2F92EE;'>#漏诊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66640, encryptionId=144966640f8, topicName=漏诊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d362645427, createdName=makuansheng, createdTime=Sat Apr 04 03:03:08 CST 2020, time=2020-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534845, encodeId=fbaa153484561, content=<a href='/topic/show?id=47ee325e539' target=_blank style='color:#2F92EE;'>#前哨淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32575, encryptionId=47ee325e539, topicName=前哨淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a89e12549488, createdName=by2013, createdTime=Sat Apr 04 03:03:08 CST 2020, time=2020-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571202, encodeId=b90115e1202fb, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Sat Apr 04 03:03:08 CST 2020, time=2020-04-04, status=1, ipAttribution=)]
    2020-04-04 sodoo
  2. [GetPortalCommentsPageByObjectIdResponse(id=1293092, encodeId=6edb12930922f, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Sat Apr 04 03:03:08 CST 2020, time=2020-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407389, encodeId=4114140e38966, content=<a href='/topic/show?id=144966640f8' target=_blank style='color:#2F92EE;'>#漏诊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66640, encryptionId=144966640f8, topicName=漏诊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d362645427, createdName=makuansheng, createdTime=Sat Apr 04 03:03:08 CST 2020, time=2020-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534845, encodeId=fbaa153484561, content=<a href='/topic/show?id=47ee325e539' target=_blank style='color:#2F92EE;'>#前哨淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32575, encryptionId=47ee325e539, topicName=前哨淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a89e12549488, createdName=by2013, createdTime=Sat Apr 04 03:03:08 CST 2020, time=2020-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571202, encodeId=b90115e1202fb, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Sat Apr 04 03:03:08 CST 2020, time=2020-04-04, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1293092, encodeId=6edb12930922f, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Sat Apr 04 03:03:08 CST 2020, time=2020-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407389, encodeId=4114140e38966, content=<a href='/topic/show?id=144966640f8' target=_blank style='color:#2F92EE;'>#漏诊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66640, encryptionId=144966640f8, topicName=漏诊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d362645427, createdName=makuansheng, createdTime=Sat Apr 04 03:03:08 CST 2020, time=2020-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534845, encodeId=fbaa153484561, content=<a href='/topic/show?id=47ee325e539' target=_blank style='color:#2F92EE;'>#前哨淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32575, encryptionId=47ee325e539, topicName=前哨淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a89e12549488, createdName=by2013, createdTime=Sat Apr 04 03:03:08 CST 2020, time=2020-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571202, encodeId=b90115e1202fb, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Sat Apr 04 03:03:08 CST 2020, time=2020-04-04, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1293092, encodeId=6edb12930922f, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Sat Apr 04 03:03:08 CST 2020, time=2020-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407389, encodeId=4114140e38966, content=<a href='/topic/show?id=144966640f8' target=_blank style='color:#2F92EE;'>#漏诊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66640, encryptionId=144966640f8, topicName=漏诊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d362645427, createdName=makuansheng, createdTime=Sat Apr 04 03:03:08 CST 2020, time=2020-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534845, encodeId=fbaa153484561, content=<a href='/topic/show?id=47ee325e539' target=_blank style='color:#2F92EE;'>#前哨淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32575, encryptionId=47ee325e539, topicName=前哨淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a89e12549488, createdName=by2013, createdTime=Sat Apr 04 03:03:08 CST 2020, time=2020-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571202, encodeId=b90115e1202fb, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Sat Apr 04 03:03:08 CST 2020, time=2020-04-04, status=1, ipAttribution=)]

相关资讯

盘点:2020年度J Clin Oncol杂志回顾汇总(三)

J Clin Oncol:2020年ASCO临床肿瘤学年度进展报告

安全性、有效性兼顾—苏鹏程教授谈疫情期间HR+乳腺癌全程管理

2020年伊始,新型冠状病毒肺炎席卷全球,截至目前为止,累计数万人感染新冠肺炎。在国家和公众的积极努力下,国内新冠肺炎疫情得以逐步控制,而境外疫情呈现日益严重态势。疫情给包括乳腺癌在内的患者就诊带来了

王建东教授专访:ADC药物发力HER2阳性乳腺癌

抗HER2药物的出现,彻底改写了HER2阳性乳腺癌患者的预后。一直以来,国内抗HER2药物可及性较差,近年随着医药改革的推动,很多在国外临床实践中得到很好验证的抗HER2药物开始进入中国市场,T-DM

杨红健教授:受体阳性乳腺癌患者治疗策略

新冠肺炎疫情牵动国人心。尽管,现在抗击疫情战役已经捷报频传,然而,仍不能掉以轻心。早在2月份钟南山院士团队就指出肿瘤患者更易感染新冠肺炎病毒。根据当前疫情形势,一切向好,但仍不能松懈。那么,在疫情期间

刘胜春教授:疫情之下乳腺癌患者注意主动防护、合理就诊

疫情当下,给乳腺癌患者乃至正常人的生活都造成了极大不便。在此情况下,国家制定了一系列惠民政策,诸如网络门诊、送药到家等,极大方便了乳腺癌患者的就诊,降低了新冠肺炎感染风险。

Brit J Cancer:成年早期体重指数和体重增加与乳腺癌风险

只有在20岁时体重指数小于23.4 kg/m2的女性中,成年期体重增加才会增加绝经后患乳腺癌的风险。